Investigational Drug Information for SHR3680
✉ Email this page to a colleague
What is the development status for investigational drug SHR3680?
SHR3680 is an investigational drug.
There have been 16 clinical trials for SHR3680.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2021.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Hypersensitivity. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Atridia Pty Ltd.
Summary for SHR3680
| US Patents | 0 |
| International Patents | 16 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-09-01) |
| Vendors | 12 |
Recent Clinical Trials for SHR3680
| Title | Sponsor | Phase |
|---|---|---|
| Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
Clinical Trial Summary for SHR3680
Top disease conditions for SHR3680
Top clinical trial sponsors for SHR3680
US Patents for SHR3680
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SHR3680
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SHR3680 | Australia | AU2013312587 | 2032-09-04 | ⤷ Try a Trial |
| SHR3680 | Brazil | BR112015004637 | 2032-09-04 | ⤷ Try a Trial |
| SHR3680 | Canada | CA2883545 | 2032-09-04 | ⤷ Try a Trial |
| SHR3680 | China | CN103958480 | 2032-09-04 | ⤷ Try a Trial |
| SHR3680 | European Patent Office | EP2894151 | 2032-09-04 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
